- Home
- BDRX vs PRFX Comparison
BDRX vs PRFX Comparison
Compare BDRX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | PRFX |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.6M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BDRX | PRFX |
|---|---|---|
| Price | $3.04 | $1.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 84.2K | ★ 329.5K |
| Earning Date | 09-12-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.58 |
| 52 Week High | $11.88 | $3.71 |
Technical Indicators
Market Signals| Indicator | BDRX | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 35.23 |
| Support Level | $2.86 | $1.80 |
| Resistance Level | $4.39 | $2.89 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | -0.14 | -0.07 |
| Stochastic Oscillator | 8.45 | 8.70 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.